• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

    6/9/22 2:38:42 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TTNP alert in real time by email
    SC 13D/A 1 titanpharma_sc13da.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 1)1

     

    Titan Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    888314606

    (CUSIP Number)

     

    DAVID E. LAZAR

    Villa 1, 14-43rd Street
    Jumeirah 2
    Dubai, United Arab Emirates

    (646) 768-8417

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    June 7, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this Schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    1The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     

     

     

    1

    NAME OF REPORTING PERSONS

     

    DAVID E. LAZAR

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS

     

    OO, PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐

     

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Portugal, Israel

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7

    SOLE VOTING POWER

     

    1,398,133

    8

    SHARED VOTING POWER

     

    43,145

    9

    SOLE DISPOSITIVE POWER

     

    1,398,133

    10

    SHARED DISPOSITIVE POWER

     

    43,145

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,441,278

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

     

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    9.9%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    2

     

     

    1

    NAME OF REPORTING PERSONS

     

    ACTIVIST INVESTING LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐

     

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New York

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

    43,145

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

    43,145

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    43,145

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐

     

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1%

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    3

     

     

    The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.

     

    Item 2. Identity and Background.

     

    Items 2 (b), (c) and (f) are hereby amended and restated to read as follows:

     

    (b) The principal business address of Activist Investing is 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036. The principal business address of Mr. Lazar is Villa 1, 14-43rd Street, Jumeirah 2, Dubai, United Arab Emirates.

     

    (c) The principal business of Activist Investing is actively investing in distressed public companies. Mr. Lazar is a private investor and the Chief Executive Officer of Activist Investing.

     

    (f) Mr. Lazar is a citizen of Portugal and Israel.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 is hereby amended and restated to read as follows:

     

    The Shares purchased by Activist Investing were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in the open market, except as otherwise noted. The Shares purchased by Mr. Lazar were purchased with personal funds (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in the open market, except as otherwise noted. The aggregate purchase price of the 43,145 Shares directly beneficially owned by Activist Investing is approximately $41,850, excluding brokerage commissions. The aggregate purchase price of the 1,398,133 Shares directly beneficially owned by David Lazar is approximately $981,489, excluding brokerage commissions.

     

    Item 5. Interest in Securities of the Issuer.

     

    Items 5(a) – (c) are hereby amended and restated to read as follows:

     

    The aggregate percentage of Shares reported owned by each person named herein is based upon 14,629,217 Shares outstanding, which is the total number of Shares outstanding as of June 7, 2022, as disclosed to the Reporting Persons on June 7, 2022.

     

    A. Activist Investing

     

      (a) As of the close of business on June 8, 2022, Activist Investing directly beneficially owned 43,145 Shares.

     

    Percentage: Less than 1%

     

      (b) 1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 43,145
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 43,145

     

    4

     

     

    B. Mr. Lazar

     

      (a) As of the close of business on June 8, 2022, Mr. Lazar directly beneficially owned 1,398,133 Shares. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the 43,145 Shares owned by Activist Investing.

     

    Percentage: Approximately 9.9%

     

      (b) 1. Sole power to vote or direct vote: 1,398,133
    2. Shared power to vote or direct vote: 43,145
    3. Sole power to dispose or direct the disposition: 1,398,133
    4. Shared power to dispose or direct the disposition: 43,145

     

      (c) The transactions in the Shares by the Reporting Persons since the filing of the Schedule 13D are set forth in Schedule A and are incorporated herein by reference.

     

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

     

    5

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: June 9, 2022

     

      ACTIVIST INVESTING LLC
       
      By:

    /s/ David E. Lazar

        Name:  David E. Lazar
        Title: Chief Executive Officer

     

      /s/ David E. Lazar
      DAVID E. LAZAR

     

    6

     

     

    SCHEDULE A

     

    Transaction in the Shares Since the Filing of the Schedule 13D

     

    Nature of Transaction  

    Shares

    Purchased

     

    Price Per

    Share($)

     

    Date of

    Purchase

                 
    DAVID E. LAZAR
                 
    Purchase of Common Stock   72,000   0.40941   06/06/2022
    Purchase of Common Stock   475,000   0.44402   06/07/2022
    Purchase of Common Stock   205,000   0.52663   06/08/2022

     

     

    1Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.4086 to $0.4096, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
    2Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.4041 to $0.4770, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
    3Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.4732 to $0.5800, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.

     

    Sch. A-1

    Get the next $TTNP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTNP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TTNP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

      NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series B Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock for an aggregate purchase price of $1,000,000. The shares have a conversion price of $3.00. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "bl

      4/11/25 4:15:09 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

      NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

      11/27/24 4:05:55 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination with KE Sdn. Bhd. ("KE"). The Merger Agreement was approved by Titan's board of directors (the "Board"). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing"), Titan will be combined with KE in a "reverse merger" transaction consisting

      8/19/24 4:11:12 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Loh Gabriel claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      5/5/25 1:50:21 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Jye Chay Weei claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      4/16/25 3:49:51 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Mokhtar Firdauz claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      4/5/24 10:14:05 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Titan Pharmaceuticals upgraded by Maxim Group with a new price target

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

      2/25/21 10:45:32 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals upgraded by Maxim Group

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy

      2/18/21 8:31:20 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals upgraded by Maxim Group with a new price target

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

      2/18/21 7:31:23 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Leadership Updates

    Live Leadership Updates

    See more
    • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

      NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

      11/27/24 4:05:55 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

      SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut

      10/16/23 4:37:23 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc.

      SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      8/21/24 8:32:38 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

      SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      4/5/24 4:34:04 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Titan Pharmaceuticals Inc.

      SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      10/4/23 5:30:18 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    SEC Filings

    See more
    • SEC Form 10-Q filed by Titan Pharmaceuticals Inc.

      10-Q - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      5/14/25 4:05:26 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Titan Pharmaceuticals Inc.

      DEFA14A - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      5/2/25 4:11:23 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Titan Pharmaceuticals Inc.

      DEF 14A - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      5/2/25 4:05:25 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care